Niagen Bioscience, Inc. acquires a comprehensive portfolio of patents covering nicotinamide riboside (NR) and its salt forms from Queen's University Belfast, establishing it as the sole owner of valuable intellectual property in the NAD+ industry.
The acquisition includes patents on the production, composition, and commercial use of NR, providing strong protection against infringers in the NAD+ industry.
With this transaction, Niagen Bioscience enhances its position in the NAD+ precursor intellectual property landscape and gains greater control over its molecules and applications.
Sole Ownership of NR Patents
Niagen Bioscience becomes the sole owner of the core patents related to NR, strengthening its position in the NAD+ industry.
Enhanced IP Protection
The acquisition of composition-of-matter patents provides robust IP protection against known forms of NAD+ precursor infringement.
Strategic Flexibility
Owning the patent portfolio offers Niagen Bioscience increased strategic and operational flexibility for its current and future applications, including pharmaceutical uses.
- The acquisition of the patent portfolio bolsters Niagen Bioscience's financial, strategic, and operational capabilities, enabling it to advance its NAD+ initiatives with greater control and flexibility.
- With over 90 issued and pending patents worldwide across NR and other NAD+ precursors, Niagen Bioscience solidifies its position as a leader in NAD+ science and innovation.
Niagen Bioscience's acquisition of the NR patent portfolio marks a significant milestone in its quest for NAD+ leadership. The strengthened IP position and strategic flexibility gained from this transaction position the company for continued success in the rapidly evolving NAD+ industry.